Skip to main content
ORTHOCELL LIMITED logo

ORTHOCELL LIMITED — Investor Relations & Filings

Ticker · OCC ISIN · AU000000OCC6 ASX Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2023-08-30 Governance Information
Country AU Australia
Listing ASX OCC

About ORTHOCELL LIMITED

https://orthocell.com/

Orthocell Limited is a regenerative medicine company focused on the development and commercialization of innovative technologies for the repair and regeneration of human soft tissue. The company’s core product portfolio includes the CelGro platform, a naturally derived collagen medical device designed to facilitate tissue repair and reconstruction in applications such as dental bone and soft tissue regeneration, nerve repair, and tendon repair. Orthocell also specializes in advanced cellular therapies, notably Ortho-ATI (Autologous Tenocyte Implantation) for treating chronic tendon injuries and Ortho-ACI (Autologous Chondrocyte Implantation) for cartilage repair. These therapies utilize a patient's own cells to restore function and structure to damaged tissues. The company aims to provide restorative solutions that improve clinical outcomes and offer alternatives to traditional surgical interventions.

Recent filings

Filing Released Lang Actions
Corporate Governance Statement 13 pages 407.1KB
Governance Information Classification · 95% confidence The document is titled 'Corporate Governance Statement' and contains detailed disclosures about the company's corporate governance practices, board structure, compliance with ASX Corporate Governance Principles and Recommendations, board composition, director independence, and related governance policies. It is a comprehensive governance report covering the financial year ending 31 August 2023. There is no indication that this is an announcement or a brief summary; rather, it is a substantive report on governance practices. This matches the description of Governance Information (CGR), which includes reports detailing the company's internal rules, board structure, and governance practices. The document length (15,000 characters) and content confirm it is a full governance statement, not a mere announcement or certification. Therefore, the appropriate classification is CGR with high confidence.
2023-08-30 English
Appendix 4G 13 pages 383.1KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a detailed governance disclosure document related to corporate governance principles and recommendations for the financial year ended 30 June 2023. The document includes a key to where governance disclosures can be found and confirms compliance with ASX Corporate Governance Council recommendations. It is not the full annual report but a governance disclosure appendix that accompanies the annual report. The document is not a report publication announcement, nor is it a certification or a brief summary. It is a governance-related disclosure document that aligns with the Governance Information (CGR) category, which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-08-30 English
Striate re-certified under new European medical device regs 3 pages 206.1KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the re-certification of a medical device (Striate+) under new European Medical Device Regulations (MDR). It discusses regulatory approval, market opportunities, partnership updates, and sales outlook. There is no indication of financial statements, audit results, board changes, earnings data, or other typical financial report content. The document is an announcement of a regulatory milestone and commercial update rather than a formal financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a report publication announcement since it does not mention the release of a report. The content is best classified as a Regulatory Filing (RNS) as it is a general regulatory announcement and commercial update that does not fit other specific categories.
2023-08-23 English
Quarterly Activity Report & Appendix 4C 10 pages 622.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Report – June 2023' and is dated 31 July 2023. It provides detailed financial and operational information for the quarter ended 30 June 2023, including cash inflows, sales figures, product updates, and management appointments. The content includes substantive financial data such as cash inflows, sales volumes, and cash balances, as well as operational highlights and strategic updates. The length of the document (15,000 characters) and the detailed financial and business analysis confirm it is a comprehensive quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2023-07-30 English
Orthocell receives A$3.17m R&D tax incentive refund 2 pages 206.3KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Orthocell has received a A$3.17 million R&D tax incentive refund for the financial year 2021/2022. It discusses the use of these funds and provides background on the company and its products. There are no financial statements, detailed financial performance data, or comprehensive report content. The document is an update on a financing-related event (receipt of a tax incentive refund) rather than a full financial report or earnings release. It is not a regulatory filing or certification. Given the nature of the announcement about receipt of funds and its impact on cash reserves, this fits best under Capital/Financing Update (CAP). The document length is just over 5,000 characters, but it is clearly an announcement rather than a full report. Therefore, the classification is CAP with high confidence.
2023-06-20 English
Change of Director's Interest Notice - Paul Anderson 2 pages 222.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares and options held before and after the change, the nature of the change (on-market purchase), and other related information. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. The document length is 4086 characters, which is typical for such notices. There is no indication that this is an announcement of a report or a certification, nor does it contain financial statements or management commentary. Therefore, the appropriate classification is Director's Dealing (DIRS).
2023-06-15 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.